Astrazeneca Ab

Nps Allelix Corporation

Nps Pharmaceuticals, Inc.

Ontario Institute for Cancer Research (oicr)

Propellon Therapeutics Inc.

Nps Allelix Biopharmaceuticals, Inc.

Ontario Institute for Cancer Research

Bradford C. Van Wagenen

Scott T. Moe

Abdelmalik Slassi

Susan M. Sheehan

Donald A. Mcleod

Daryl L. Smith

Thomas M. Stormann

Methvin Benjamin Isaac

Ian Egle

Louise G Edwards

Tao Xin

Fupeng Ma

Joshua Clayton

James Empfield

Jalaj Arora

Tomislav Stefanac

Babu Joseph

David Wensbo

Ahmed Mamai

Donald A McLeod

Bradford C Van Wagenen

Rima Al-Awar

David Uehling

Gennady Poda

Pandiaraju Subramanian

Brian Wilson

Thomas M Stormann

Rebecca Urbanek

Gary Steelman

Alexander Minidis

Radhakrishnan Ukkiramapandian

Sally Walsh

Martin Johansson

Anh My Chau

Yong Liu

Annika Kers

James Jeffrey Folmer

Jennifer Frey

Carlos Armando Zepeda-Velazquez

Karin Staaf

Michael Prakesch

Scott T Moe

Daryl Lynn Smith

Anne O'Brien

Susan M Sheehan

Iain Watson

Ashok Tehim

Shawn Maddaford

Kenneth Lars Granberg

Dean Brown

Peter Dove

Andreas Christer Wallberg

Guy A Higgins

Krzysztof Swierczek

Erwan Arzel

Karolina Nilsson

Helena Gyback

Ulrika Yngve

Justin-Alexander Morin

Julia Katheleen Stille

Bradford Van Wagenen

Björn Holm

Mats Nagard

Johan Malmberg

Alexander Mindis

Julia Kathleen Stille

Tau Xin

Tom Stefanac

Don McLeod

Caroline Eriksson

Veronica Profir

Per-Olov Bergstrom

John Malmberg

Karin Oscarsson

Mangus Waldman

Christoffer Osterwall

William Michne

Daryl L Smith

Donald A Mcleod

Donald Mcleod

Thomas Stormann

The present application is directed to compounds of Formula I:

Substituted carboxamides as inhibitors of WDR5 protein-protein binding

The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.

Deuterated compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners. 

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer. 

Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof

The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer. 

Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders

The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias. wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R; Ris chosen from: alkyl or haloalkyl; Ris chosen from: H, C(O)R, C(O)OR, SO2Ror C(O)NRR; R, Rand Rare independently chosen from: H or alkyl; Rand Rare independently chosen from: H or alkyl; and Ris chosen from: OH, CN, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, C(O)R, C(O)OR, SO2Ror C(O)NRR. 

Use of D-serine derivatives for the treatment of anxiety disorders

Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842

Compounds of Formula (I) wherein Rand Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same. 

Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators&#x2014;842

Compounds of formula I: wherein R, R, R, R, R, R, R, R, Rand n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.

Metabotropic glutamate-receptor-potentiating isoindolones

The present invention is directed to compounds of formula I: wherein R, R, R, R, R, R, R, R, Rand n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Isoindolone compounds and their use as metabotropic glutamate receptor potentiators

Compounds of formula (I) wherein Ris as well as pharmaceutically acceptable salts, hydrates and/or enantiomers thereof are useful as compounds that exhibit activity at metabotropic glutamate receptors.

Pharmaceutically active compounds containing tetrazolyl and triazolyl rings

Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: wherein Ar, Ar, A, X, Y, m, n and R, R, R, Rand Rare as described in the specification, processes for their preparation, pharmaceutical formulations comprising them and their use in therapy, particularly in the therapy of neurological and psychiatric disorders associated with glutamate dysfunction.

Piperazines and piperidines as Mglur5 potentiators

Substituted isoindolones and their use as metabotropic glutamate receptor potentiators

Growing community of inventors

CA

Methvin Benjamin Isaac